evipedia.ai
← Back

Dalargin for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Dalargin, a laboratory-made peptide copy of one of the body's own opioid-like signals that stays out of the brain, is an injected prescription medicine in Russia and Ukraine for ulcers and inflammation of the pancreas. Most favourable studies come from its developer, and in the one Western-standard trial it healed ulcers less well than a standard ulcer medicine. Harms are modest: falling blood pressure, unpredictable heart rate, rare allergic reactions. (Full Review)

Protocol

Ulcer-disease regimen
1–2 mg per dose
Intramuscular or intravenous, maximum 5 mg daily, for 3–4 weeks; 30–50 mg total per course
Acute pancreatitis regimen
5 mg intravenously once or twice daily
After a 2 mg first dose, for 4–6 days; pancreatic necrosis: 5 mg every 6–8 hours for 2–6 days
Competing approach — nasal route
1 mg intranasally twice daily
For 10 days, repeated three times over three months, in coronary disease with metabolic syndrome
Time to effect
Ulcer healing
21–22 days
Mean time to ulcer closure across series, with most healing by day 28
Pneumonia recovery
2.54 days
Clinical stability or discharge on the inhaled form, versus 3.38 days on placebo; clinical cure by day 10 in 54.8% versus 36.1%
Blood lipids and stress hormones
3 months
Marker changes in coronary disease measured after 10-day courses over three months

Benefits

Contraindications
  • Known hypersensitivity to the active substance
  • Low blood pressure (pronounced; below 100/60 mm Hg)
  • Acute infectious process
  • Pregnancy and breastfeeding
  • Under 18 years of age
  • Heart failure of New York Heart Association class IV or chronic kidney disease of stage 3a or worse (filtration below 60)
  • Heart attack or stroke within the past 6 months, or surgical risk class IV–V on the American Society of Anesthesiologists scale
  • Diagnosed psychiatric or neuromuscular disorder
  • Solvents other than 0.9% sodium chloride
    •
Key Interactions
  • Opioid analgesics (morphine, fentanyl): Caution
  • Opioid blockers (naloxone, naltrexone): Avoid together
  • Blood-pressure-lowering medicines (captopril, amlodipine): Monitor
  • Acid-suppressing medicines (famotidine, cimetidine): Caution for additive effect, not harm
  • Over-the-counter anti-inflammatory pain medicines (ibuprofen, aspirin): Caution (theoretical)
  • Over-the-counter sedating antihistamines (diphenhydramine): Caution (theoretical)
  • Supplements that lower blood pressure (magnesium, garlic extract): Caution (theoretical) for additive hypotension
    •

Risk & Side Effects

  • High:
  • Medium: Fall in blood pressure, with dizziness and blurred vision; heart-rate disturbance in both directions
    •
  • Low: Allergic and infusion-type reactions; nausea and upper abdominal pain
    •
  • Speculative: Unpredictable immune modulation; loss of effect at higher doses; carrier-related toxicity in brain-delivery formulations
    •

Monitoring

Marker Target Why
Blood pressure (sitting and standing) No established target; track change from own baseline Safety check for the labelled pressure fall
Heart rate 60–100 beats/min at rest Safety check: rate may fall or rise unpredictably
Serum amylase and lipase Amylase 25–125 U/L; lipase 0–160 U/L Drug suppresses pancreatic enzyme output
Fasting insulin 2–25 µIU/mL Fell with added dalargin in the coronary trial
Triglycerides and high-density lipoprotein cholesterol No established target; track change from own baseline Moved further with added dalargin
Interleukin-6 No established target; track change from own baseline Inflammatory signal that fell in the coronary trial
Estimated kidney filtration rate No established target; track change from own baseline Safety check: advanced kidney disease was a trial exclusion

Cadence: Baseline before a course; blood pressure and heart rate before and about 30 minutes after each of the first few doses, then daily; pancreatic enzymes daily through a 4–6 day course; metabolic and inflammatory markers at the end of a 10-day course and again after three months

Qualitative Assessment

  • Light-headedness or blurred vision on standing
  • Upper abdominal pain, heartburn and nausea
  • Redness, rash or itching at the injection site, and any facial flushing or swelling after a dose
  • Chills, fever or chest tightness within an hour of a dose
  • Walking distance before leg or chest discomfort
  • Day-to-day energy and sense of stress load
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.